Hematology/Oncology

Top Story

UCLA researchers receive grant to study combination therapy for lung cancer

September 18, 2018

Researchers at UCLA received $12 million to conduct a study of pembrolizumab in combination with patients’ genetically modified immune cells for treatment of advanced lung cancer.

Steven M. Dubinett, MD, chief of the division of pulmonary and critical care medicine at UCLA David Geffen School of Medicine and a member of Jonsson Comprehensive Cancer Center and UCLA Broad Stem Cell Research Center, and colleagues will initiate the clinical trial.

In the Journals Plus

Brentuximab vedotin data ‘practice changing’ for older patients with Hodgkin lymphoma

September 18, 2018

Brentuximab vedotin administered sequentially before and after standard chemotherapy appeared effective and safe for older patients with previously untreated Hodgkin…

In the Journals

Team-based health care improves patient outcomes, physician well-being

September 18, 2018

Implementing optimal team-based health care is associated with improvements in patient outcomes, the efficiency of care and the well-being and satisfaction of…

In the Journals

Burnout frequency varies by specialty, but exact prevalence unclear

September 18, 2018

Symptoms of burnout and career choice regret were common among U.S. resident physicians, but differed substantially by clinical specialty, according to findings recently…

In the Journals Plus

Dose-dense chemotherapy improves bladder cancer outcomes following cystectomy

September 18, 2018

Neoadjuvant chemotherapy comprised of a dose-dense combination of methotrexate, vinblastine, doxorubicin and cisplatin improved response rates among patients with…

More Headlines »

CME